Literature DB >> 17012250

Probing the human kinome for kinases involved in pancreatic cancer cell survival and gemcitabine resistance.

Valentin Giroux1, Juan Iovanna, Jean-Charles Dagorn.   

Abstract

Except for gemcitabine, chemotherapeutic agents are ineffective with pancreatic adenocarcinoma because this cancer is resistant to apoptosis induction. Involvement of specific kinases in such resistance is likely. We developed a systematic strategy to screen the human kinome and select kinases whose inhibition in pancreatic cancer cells can increase 1) spontaneous apoptosis or 2) gemcitabine-induced apoptosis. The pancreatic adenocarcinoma cell line MiaPaCa-2 was transfected with 645 pairs of siRNAs directed to all human kinases. The same experiment was conducted in cells treated with 150 microM gemcitabine. Apoptosis was measured after 2 days and the results were normalized for cell viability. A panel of 56 kinases whose inhibition increased spontaneous apoptosis by at least 50% was established. Ten of them gave similar results on Panc1 and BxPC3 pancreatic adenocarcinoma cell lines. A panel of 83 kinases whose inhibition increased gemcitabine-induced apoptosis by 50% or more was also established. Twelve kinases appeared in both panels. A cumulative increase in apoptosis was observed when inhibiting simultaneously several kinases. Such a systematic approach allowed characterization of all kinases involved in pancreatic cancer cell survival and resistance to gemcitabine. Inhibitors of these kinases, used alone or in combination, might improve the treatment of pancreatic adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17012250     DOI: 10.1096/fj.06-6239com

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  38 in total

1.  RNAi screening identifies TAK1 as a potential target for the enhanced efficacy of topoisomerase inhibitors.

Authors:  S E Martin; Z-H Wu; K Gehlhaus; T L Jones; Y-W Zhang; R Guha; S Miyamoto; Y Pommier; N J Caplen
Journal:  Curr Cancer Drug Targets       Date:  2011-10       Impact factor: 3.428

2.  Imexon induces an oxidative endoplasmic reticulum stress response in pancreatic cancer cells.

Authors:  Elena V Sheveleva; Terry H Landowski; Betty K Samulitis; Geoffrey Bartholomeusz; Garth Powis; Robert T Dorr
Journal:  Mol Cancer Res       Date:  2012-01-24       Impact factor: 5.852

Review 3.  Exploiting replicative stress to treat cancer.

Authors:  Matthias Dobbelstein; Claus Storgaard Sørensen
Journal:  Nat Rev Drug Discov       Date:  2015-05-08       Impact factor: 84.694

4.  Protein kinase D2 is a novel regulator of glioblastoma growth and tumor formation.

Authors:  Ninel Azoitei; Alexander Kleger; Nina Schoo; Dietmar Rudolf Thal; Cornelia Brunner; Ganesh Varma Pusapati; Alina Filatova; Felicitas Genze; Peter Möller; Til Acker; Rainer Kuefer; Johan Van Lint; Heinrich Baust; Guido Adler; Thomas Seufferlein
Journal:  Neuro Oncol       Date:  2011-07       Impact factor: 12.300

5.  Type II p21-activated kinases (PAKs) are regulated by an autoinhibitory pseudosubstrate.

Authors:  Byung Hak Ha; Matthew J Davis; Catherine Chen; Hua Jane Lou; Jia Gao; Rong Zhang; Michael Krauthammer; Ruth Halaban; Joseph Schlessinger; Benjamin E Turk; Titus J Boggon
Journal:  Proc Natl Acad Sci U S A       Date:  2012-09-17       Impact factor: 11.205

6.  Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors.

Authors:  Betty K Samulitis; Kelvin W Pond; Erika Pond; Anne E Cress; Hitendra Patel; Lee Wisner; Charmi Patel; Robert T Dorr; Terry H Landowski
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

Review 7.  Adenylate kinase and AMP signaling networks: metabolic monitoring, signal communication and body energy sensing.

Authors:  Petras Dzeja; Andre Terzic
Journal:  Int J Mol Sci       Date:  2009-04-17       Impact factor: 6.208

8.  Cytotoxicity screening of Bangladeshi medicinal plant extracts on pancreatic cancer cells.

Authors:  Sherine George; Siddharth V Bhalerao; Erich A Lidstone; Irfan S Ahmad; Atiya Abbasi; Brian T Cunningham; Kenneth L Watkin
Journal:  BMC Complement Altern Med       Date:  2010-09-17       Impact factor: 3.659

9.  Enhancing chemosensitivity to gemcitabine via RNA interference targeting the catalytic subunits of protein kinase CK2 in human pancreatic cancer cells.

Authors:  Jan N Kreutzer; Maria Ruzzene; Barbara Guerra
Journal:  BMC Cancer       Date:  2010-08-19       Impact factor: 4.430

10.  Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer.

Authors:  David O Azorsa; Irma M Gonzales; Gargi D Basu; Ashish Choudhary; Shilpi Arora; Kristen M Bisanz; Jeffrey A Kiefer; Meredith C Henderson; Jeffrey M Trent; Daniel D Von Hoff; Spyro Mousses
Journal:  J Transl Med       Date:  2009-06-11       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.